A S X A N N O U N C E M E N T 12 November 2026 First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company...
First FDA Breakthrough Therapy designation in PSMA PET
Filed with ASX · · 7 pages · English
Summary by 6ix AI
This designation is intended to expedite the development and review of drugs that show substantial improvement over existing therapies for serious conditions. The designation was supported by data from clinical trials indicating enhanced diagnostic performance compared to standard care imaging. Clarity is currently conducting two Phase III trials for this product, with topline data expected in the near future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Clarity Pharmaceuticals
- Ceasing to be a substantial holder
- Trading Halt
- Pause in Trading
- Becoming a substantial holder
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Clarity Pharmaceuticals
All Clarity Pharmaceuticals news releasesFollow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals